AF
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials : results from the Pembro-real 5Y global registry | Journal for immunotherapy of cancer |  | 2025 | 71 | 15 | ||
| Metastatic gastric cancer : synergizing and sequencing targeted therapy with first-line immunotherapy | Immunotherapy |  | 2024 | 18 | 0 | ||
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | 2024 | 62 | 71 | ||
| Oncogenic alterations in advanced NSCLC : a molecular super-highway | Biomarker research | | 2024 | 68 | 128 | ||
| Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer | Clinical medicine insights. Oncology | | 2023 | 81 | 111 | ||
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | 2023 | 85 | 24 | ||
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | 2023 | 45 | 59 | ||
| Precision oncology in advanced non-small cell lung cancer in 2022: a narrative review | | 2023 | 93 | 163 | |||
| Current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer | Current oncology reports | | 2023 | 89 | 54 | ||
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | 2023 | 105 | 105 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 88 | 52 | ||
| RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives | Pharmacology & therapeutics | | 2023 | 72 | 116 | ||
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | 2023 | 48 | 75 | ||
| Cellular therapy in NSCLC : between myth and reality | Current oncology reports | | 2023 | 44 | 113 | ||
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | 2022 | 235 | 147 | ||
| The Landscape of Immunotherapy Resistance in NSCLC | Frontiers in oncology | | 2022 | 138 | 115 | ||
| Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study | Translational lung cancer research | | 2022 | 58 | 39 | ||
| SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort | Microorganisms | | 2021 | 195 | 104 | ||
| The impact of variant allele frequency in EGFR mutated NSCLCc patients on targeted therapy | Frontiers in Oncology | | 2021 | 368 | 165 | ||
| COVID-19 and lung cancer: risks, mechanisms and treatment interactions | Journal for immunotherapy of cancer | | 2020 | 82 | 23 | ||
| Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer | Cancer Genomics & Proteomics | | 2020 | 217 | 96 | ||
| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes | Scientific Reports | | 2020 | 325 | 312 | ||
| Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors | Frontiers in Oncology | | 2020 | 292 | 236 | ||
| Mutations constitutionnelles BRCA1/BRCA2 et hématotoxicité chimio-induite chez les patientes avec un cancer du sein | | 2020 | 526 | 102 | |||
| Facteurs de croissance granulocytaire dans le traitement curatif desneutropénies fébriles | Revue médicale suisse | | 2020 | 294 | 0 | ||
| Targeted Therapies in Early Stage NSCLC : Hype or Hope? | International journal of molecular sciences | | 2020 | 69 | 77 | ||
| Prostate cancer nonascitic peritoneal carcinomatosis after robot-assisted laparoscopic radical prostatectomy: 3 case reports and review of the literature | Urology | | 2020 | 318 | 0 | ||
| BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients | Breast Cancer Research and Treatment | | 2019 | 436 | 3 | ||
| Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists | Canadian Journal of Cardiology | | 2018 | 532 | 2 | ||
| Chimiothérapie de maintenance : futile ou utile ? | Revue médicale suisse | | 2015 | 477 | 190 |
